Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Monoclonal antibody therapies for solid tumors.

Tassev DV, Cheung NK.

Expert Opin Biol Ther. 2009 Mar;9(3):341-53. doi: 10.1517/14712590802715764 . Review.

PMID:
19216623
2.

Approved monoclonal antibodies for cancer therapy.

Boyiadzis M, Foon KA.

Expert Opin Biol Ther. 2008 Aug;8(8):1151-8. doi: 10.1517/14712598.8.8.1151 . Review.

PMID:
18613766
3.

Anticancer antibodies.

Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M.

Am J Clin Pathol. 2003 Apr;119(4):472-85. Review.

PMID:
12710120
4.

Comparing antibody and small-molecule therapies for cancer.

Imai K, Takaoka A.

Nat Rev Cancer. 2006 Sep;6(9):714-27. Review.

PMID:
16929325
5.

Antibody-based therapeutics: focus on prostate cancer.

Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Millowsky MI, Bander NH.

Cancer Metastasis Rev. 2005 Dec;24(4):521-37. Review.

PMID:
16408160
6.

[Monoclonal antibody for cancer treatment].

Achiwa H, Sato S, Ueda R.

Gan To Kagaku Ryoho. 2002 Apr;29(4):495-501. Review. Japanese.

PMID:
11977531
7.

[An overview of antibody therapy against cancer].

Taniguchi H, Imai K.

Nihon Rinsho. 2012 Dec;70(12):2087-92. Review. Japanese.

PMID:
23259378
8.

Antibody-based therapeutics in oncology.

Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M.

Expert Rev Anticancer Ther. 2003 Feb;3(1):107-21. Review.

PMID:
12597355
9.

Development trends for monoclonal antibody cancer therapeutics.

Reichert JM, Valge-Archer VE.

Nat Rev Drug Discov. 2007 May;6(5):349-56. Review.

PMID:
17431406
10.

Development of humanized antibodies as cancer therapeutics.

Qu Z, Griffiths GL, Wegener WA, Chang CH, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.

Methods. 2005 May;36(1):84-95.

PMID:
15848077
11.
12.

Recombinant antibodies for cancer therapy.

Deonarain MP.

Expert Opin Biol Ther. 2008 Aug;8(8):1123-41. doi: 10.1517/14712598.8.8.1123 . Review.

PMID:
18613764
13.

Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.

Krauss J, Arndt MA, Dübel S, Rybak SM.

Curr Pharm Biotechnol. 2008 Jun;9(3):231-4. Review.

PMID:
18673289
14.

Monoclonal antibodies in therapy of solid tumors.

Heimann DM, Weiner LM.

Surg Oncol Clin N Am. 2007 Oct;16(4):775-92, viii. Review.

PMID:
18022544
15.

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.

Krieg AM.

Oncogene. 2008 Jan 7;27(2):161-7. doi: 10.1038/sj.onc.1210911. Review.

PMID:
18176597
16.

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications.

Reff ME, Heard C.

Crit Rev Oncol Hematol. 2001 Oct;40(1):25-35. Review.

PMID:
11578914
17.

Immunoconjugates against solid tumors: mind the gap.

Ricart AD.

Clin Pharmacol Ther. 2011 Apr;89(4):513-23. doi: 10.1038/clpt.2011.8. Epub 2011 Mar 2. Review.

PMID:
21368753
18.

Molecular targeted therapies for solid tumors: management of side effects.

Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J.

Onkologie. 2009 Mar;32(3):129-38. doi: 10.1159/000194949. Epub 2009 Feb 16. Review.

PMID:
19295254
19.

Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.

Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y.

Hum Antibodies. 2009;18(3):81-100. doi: 10.3233/HAB-2009-0204. Review.

PMID:
19729803
20.

The next generation of antibody-drug conjugates comes of age.

Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N.

Discov Med. 2010 Oct;10(53):329-39. Review.

Supplemental Content

Support Center